

What the Science Says About Marijuana....

Comprehensive Bibliography of Scientific Research on Health Effects of Marijuana

1. Carlini, E.A. (2004), *The Good and Bad Effects of trans-delta-9-tetrahydrocannabinol on Humans*, Toxicol 44: 461-67.
2. MacLeod, John, Oakes, Rachel, et al. (2004), *Psychological and Social Sequelae of Cannabis and Other Illicit Drug Use by Young People: A systematic review of longitudinal, general population studies*, Lancet 363: 1579-88.
3. Guy, Geoffrey W., Whittle, Brian A. and Phillip J. Robson, eds., The Medicinal Uses of Cannabis and Cannabinoids, Pharmaceutical Press (Britain 2004).
4. Movig, K.L.L., Mathijssen, M.P.M., et al. (2004), *Psychoactive Substance Use and the Risk of Motor Vehicle Accidents*, Accident Analysis and Prevention 36: 631-36.
5. Musty, Richard E., and Rita Rossi (2001), *Effects of Smoked Cannabis and Oral delta9-Tetrahydrocannabinol on Nausea and Emesis After Cancer Chemotherapy: A review of state clinical trials*, Journal of Cannabis Therapeutics 1(1): 43-56.
6. Smith, Neil T. (2002), *A Review of the Published Literature into Cannabis Withdrawal Symptoms in Human Users*, Addiction 97: 621-32.
7. Mello, Nancy K. and Mendelson, Jack H. (1987), *Operant Analysis of Human Drug Self-Administration: Marijuana, Alcohol, Heroin and Polydrug Use*, available at: <http://www.addictionscience.net/MARPADc25.htm>.
8. Mikuriya, Tod H. (2004), *Cannabis as a Substitute for Alcohol: A Harm-Reduction Approach*, Journal of Cannabis Therapeutics 4(1): 79-93.
9. Labigalini, E., Jr., Rodrigues, L.R., and D.X. Da Silveira (1999), Abstract, *Therapeutic Use of Cannabis by Crack Addicts in Brazil*, Journal of Psychoactive Drugs 4: 451-55.
10. Russo, Ethan, Mathre, Mary Lynn, et al. (2002), *Chronic Cannabis Use in the Compassionate Investigational New Drug Program: An examination of benefits and adverse effects of legal clinic cannabis*, Journal of Cannabis Therapeutics 2: 3-57.
11. Dreher, Melanie (2002), *Crack Heads and Roots Daughters: The therapeutic use of cannabis in Jamaica*, Journal of Cannabis Therapeutics 2(3/4): 119-31.
12. Gieringer, Dale, St. Laurent, Joseph, and Scott Goodrich (2004), *Cannabis Vaporizer Combines Efficient Delivery of THC with Effective Suppression of Pyrolytic Compounds*, Journal of Cannabis Therapeutics 4(1): 7-27.
13. Sidney, Stephen, Beck, Jerome E., et al. (1997), *Marijuana Use and Mortality*, American Journal of Public Health 87(4): 585.
14. Sidney, Stephen, M.D., M.P.H. (2002), *Cardiovascular Consequences of Marijuana Use*, Journal of Clinical Pharmacology 42: 64S-70S.
15. Mittleman, Murray A. M.D., Dr.Ph., Lewis, Rebecca A., et al. (2001), *Triggering Myocardial Infarction by Marijuana*, Circulation 103(23): 2805-09.
16. Steffens, Sabine, Veillard, Niels R., et al. (2005), *Low Dose Oral Cannabinoid Therapy Reduces Progression of Atherosclerosis in Mice*, Nature 434: 782-86.
17. Iverson, Leslie (2005), *Long-Term Effects of Exposure to Cannabis*, Current Opinion in Pharmacology 5: 69-72.

18. Schiffman, Jason, Nakamura, Brad, et al. (2005), *Symptoms of Schizotypy Precede Cannabis Use*, Psychiatry Research 134: 37-42.
19. Hall, Wayne, Christie, MacDonald, and David Currow (2005), *Cannabinoids and Cancer: Causation, remediation, and palliation*, Lancet Oncology 6: 35-42.
20. Guzmán, Manuel (2003), Review, *Cannabinoids: Potential anticancer agents*, Nature 3: 745-55.
21. Maccarrone, M., and A. Finazzi-Agro (2003), Review, *The Endocannabinoid System, Anandamide and the Regulation of Mammalian Cell Apoptosis*, Cell Death and Differentiation 10: 946-55.
22. Russo, Ethan (2002), *Cannabis Treatments in Obstetrics and Gynecology: A historical review*, Journal of Cannabis Therapeutics 2(3/4): 5-35.
23. Robert Melamede, *Harm Reduction: the Cannabis Paradox* (2005), peer reviewed and approved for publication in the *Harm Reduction Journal*
24. Colhoun, Helen M., McKeigue, Paul M., and George Davey Smith (2003), *Problems of Reporting Genetic Associations With Complex Outcomes*. Lancet 361: 865-72.
25. Macleod, J., Oakes, R., et. al. (2004), *Psychological and Social Sequelae of Cannabis and Other Illicit Drug Use by Young People: A systematic review of longitudinal, general population studies*. Lancet 363: 1579-88.
26. Macleod, J., Oakes, R., et al. (2004), *How Strong is the Evidence that Illicit Drug Use by Young People is an Important Cause of Psychological or Social Harm? Methodological and policy implications of a systematic review of longitudinal, general population studies*. Drugs: Education, Prevention and Policy 11(4): 281-97.
27. Reinerman, Craig, Ph.D., Cohen, Peter D.A., Ph.D., and Hendrien L. Kaal, Ph.D. (2004), *The Limited Relevance of Drug Policy: Cannabis in Amsterdam and in San Francisco*. Am. Journal of Pub. Health 94(5): 836-42.
28. *The Classification of Cannabis Under the Misuse of Drugs Act 1971*, Advisory Council on the Misuse of Drugs 2002 (London, U.K.).
29. *Your Government is Lying to You (Again) About Marijuana: A Refutation of the Drug Czar's "Open Letter to America's Prosecutors,"* The National Organization for the Reform of Marijuana Laws (NORML) (Washington, D.C.).
30. Earleywine, Mitch, Understanding Marijuana: A New Look at the Scientific Evidence (Oxford University Press, 2002), "Cannabis Pharmacology," Chapter 6.
31. Senate of Canada: Special Committee on Illegal Drugs. 37th Parliament, 1st Session. *Cannabis: Our Position for a Canadian Public Policy*, Summary Report (Sept. 2002).
32. Senate of Canada: Special Committee on Illegal Drugs. 37th Parliament, 1st Session. *Cannabis: Our Position for a Canadian Public Policy*, "Cannabis: From Plant to Joint," Chapter 5 (Sept. 2002).
33. Earleywine, Mitch, Understanding Marijuana: A New Look at the Scientific Evidence (Oxford University Press, 2002), References (listing approximately 600 reference sources).
34. Pacula, R. and Kilmer, B., *Marijuana and Crime: Is There a Connection Beyond Prohibition?*, National Bureau of Economic Research (Oct. 2003).
35. Fals-Stewart, W. et al., *Intimate Partner Violence and Substance Abuse: A Longitudinal Day-to-Day Examination*, 28 Addictive Behaviors 1555 (2003).
36. Putnins, A., *Substance Use and the Prediction of Young Offender Recidivism*, 22 Drug and Alcohol Review 401 (2003).

37. Earleywine, Mitch, Understanding Marijuana: A New Look at the Scientific Evidence (Oxford University Press, 2002), "Stepping Stones, Gateways, and the Prevention of Drug Problems," Chapter 3.
38. Sidney, S., et al., *Marijuana Use and Cancer Incidence, California, United States*, 8 Cancer Causes and Control 722 (1997).
39. Breidt, B., et al., *Short Term Effects of Cannabinoids of Immune Phenotype and Function in HIV-1-Infected Patients*, 42 Journal of Clinical Pharmacology 82S (2002).
40. Grant, I., et al., *Non-Acute (Residual) Neurocognitive Effects of Cannabis Use: A Meta-Analytic Study*, 9 Journal of International Neuropsychological Society 679 (2002).
41. Jones, S. and Howl, John, *Cannabinoid Receptor Systems Therapeutic Targets for Tumor Intervention*, 7 Expert Opinion 749 (2003).
42. Iverson, L., *Cannabis and the Brain*, 126 Brain 1252 (2003).
43. DSM-IV criteria for substance abuse and substance dependence.
44. "Trends in Initiation of Substance Use," National Survey on Drug Use and Health, Chapter 6 (2002).
45. "Discussion," National Survey on Drug Use and Health, Chapter 10 (2002).
46. Morral, A., et al., *Reassessing the Marijuana Gateway Effect*, 97 Addiction 1493 (2002).
47. Senate of Canada: Special Committee on Illegal Drugs. 37th Parliament, 1st Session. *Cannibis: Our Position for a Canadian Public Policy*, "Stepping Stone to Other Drugs?" Chapter 6 (Sept 2002).
48. Earleywine, Mitch, Understanding Marijuana: A New Look at the Scientific Evidence (Oxford University Press 2002), "Social Problems," Chapter 9.
49. Hall, W., et al., *The Health and Psychological Effects of Cannabis Use*, National Drug and Alcohol Research Centre, University of New South Wales (2001).
50. Wei, E.H., et al., *Teasing Apart the Developmental Associations Between Alcohol and Marijuana Use and Violence*, 20 Journal of Contemporary Criminal Justice 166 (2004).
51. Mathias, P., et al., *Effects of Varying Marijuana Potency on Deposition of Tar and Delta-9 THC in the Lung During Smoking*, 58 Pharmacology Biochemistry and Behavior 1145 (1997).
52. Drug and Alcohol Services Information System, The DASIS Report (March 29, 2002).
53. King, L., *An Overview of Cannabis Potency in Europe*, European Monitoring Centre for Drugs and Drug Addiction (2004).
54. A Report of the National Commission on Ganja to Rt. Hon. P.J. Patterson, Q.C., M.P. Prime Minister of Jamaica, August 7, 2001.
55. *An Analysis of Marijuana Policy*, National Research Council, National Academy of Science, 1982.
56. Heishman, S., et al., *Effects of Tetrahydrocannabinol Content on Marijuana Smoking Behavior, Subjective Reports, and Performance*, 34 Pharmacology Biochemistry and Behavior 173 (1989).
57. *Marihuana: A Signal of Misunderstanding*, The Report of the National Commission on Marihuana and Drug Abuse, Commissioned by President Richard Nixon (1972).

58. Joy, J., et al., *Marijuana and Medicine: Assessing the Science Base*, Institute of Medicine, Division of Neuroscience and Behavioral Health (1999).
59. Opinion and Recommended Ruling, Findings of Fact, Conclusions of Law and Decision of Administrative Law Judge. *In the Matter of Marijuana Rescheduling Petition*, Docket No. 86-22. Francis L. Young, Administrative Law Judge, U.S. Dept. of Justice, Drug Enforcement Administration (Sept. 6 1988).
60. Mikuriya, T., M.D., *Physical, Mental and Moral Effects of Marijuana: The Indian Hemp Drugs Commission Report* (1984).
61. van den Bree, M., and Pickworth, W., *Risk Factors Predicting Changes in Marijuana Involvement in Teenagers*, 62 Arch Gen Psychiatry (2005).
62. *The Government's Drugs Policy: Is it Working?* Home Affairs Committee, House of Commons, United Kingdom Parliament (2002).